Despite this failure, in vitro experiments demonstrated the ability of these cells to recognize the metastatic tumor cells and respond with stronger cytotoxicity than all other CD8+ T cell types, suggesting that in vivo TRM cell responses are likely suppressed in some contexts [42]. The gene discussed is CD8A; the disease is neoplasm.